Scholar Rock HoldingFRA:2QK -0.02%30 EV-to-FCF is -21.37 as of Jul. 07, 2026. GuruFocus rates FRA:2QK with a GF Score™ of 30/100. The stock has 5 warning signs investors should review. Among 329 Biotechnology companies, Scholar Rock Holding ranks worse than 303951.06% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Scholar Rock Holding's Enterprise Value is €5,583.27 Mil.
Scholar Rock Holding's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-261.27 Mil. Therefore, Scholar Rock Holding's EV-to-FCF for today is -21.37.
The historical rank and industry rank for Scholar Rock Holding's EV-to-FCF or its related term are showing as below:
FRA:2QK'
s EV-to-FCF Range Over the Past 10 Years
Min: -31.09 Med: -6.11 Max: 36.81
Current: -20.92
During the past 10 years, the highest EV-to-FCF of Scholar Rock Holding was 36.81. The lowest was -31.09. And the median was -6.11.
FRA:2QK's EV-to-FCF is ranked worse than 100% of 329
companies
in the Biotechnology industry
Industry Median: 16.38
vs FRA:2QK: -20.92
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Scholar Rock Holding (FRA:2QK) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Scholar Rock Holding's PE Ratio (TTM) for today is calculated as:
Scholar Rock Holding's share price for today is €48.14.
Scholar Rock Holding's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.087.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Scholar Rock Holding EV-to-FCF Related Terms
Scholar Rock Holding EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Scholar Rock Holding's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Scholar Rock Holding's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scholar Rock Holding EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scholar Rock Holding's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Scholar Rock Holding's EV-to-FCF falls into.
Scholar Rock Holding's current Enterprise Value is €5,583.27 Mil.
Scholar Rock Holding's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-261.27 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scholar Rock Holding (FRA:2QK) has a EV-to-FCF of -21.37 as of Jul. 07, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Scholar Rock Holding and its competitors. According to the industry distribution chart, Scholar Rock Holding ranks #999999 out of 329 companies in the Biotechnology industry.
Is Scholar Rock Holding's EV-to-FCF too high?
Scholar Rock Holding's current EV-to-FCF is -21.37. Based on the distribution chart, Scholar Rock Holding ranks #999999 out of 329 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Scholar Rock Holding has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Scholar Rock Holding's EV-to-FCF compare to COGT and CGON?
According to the Biotechnology industry distribution chart, Scholar Rock Holding ranks #999999 out of 329 companies for EV-to-FCF. This places Scholar Rock Holding in the lower half of its industry. The industry median EV-to-FCF is 16.38. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.38, based on 329 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Scholar Rock Holding and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scholar Rock Holding's current EV-to-FCF is -21.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scholar Rock Holding stock overvalued right now?
Scholar Rock Holding (FRA:2QK) has a current EV-to-FCF of -21.37. The current EV-to-FCF is -21.37. Scholar Rock Holding's overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Scholar Rock Holding (FRA:2QK), the current EV-to-FCF is -21.37 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
30GF Score
Get the complete analysis for FRA:2QK
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2QK has been successfully added to your 
